Microneedle delivery of H5N1 influenza virus-like particles to the skin induces long-lasting B- and T-Cell responses in mice by Song, J. M. et al.
  Published Ahead of Print 14 July 2010. 
10.1128/CVI.00100-10. 
2010, 17(9):1381. DOI:Clin. Vaccine Immunol. 
Sang-Moo Kang
Donis, Mark R. Prausnitz, Richard W. Compans and 
Li-Mei Chen, Fu-Shi Quan, James C. Birchall, Ruben O.
Pearton, C. Todd Davis, Dae-Goon Yoo, Kyoung-Mi Park, 
Jae-Min Song, Yeu-Chun Kim, Aleksandr S. Lipatov, Marc
 
Mice
Long-Lasting B- and T-Cell Responses in
Virus-Like Particles to the Skin Induces 
Microneedle Delivery of H5N1 Influenza
http://cvi.asm.org/content/17/9/1381
Updated information and services can be found at: 
These include:
REFERENCES
http://cvi.asm.org/content/17/9/1381#ref-list-1at: 
This article cites 53 articles, 10 of which can be accessed free
CONTENT ALERTS
 more»articles cite this article), 
Receive: RSS Feeds, eTOCs, free email alerts (when new
http://journals.asm.org/site/misc/reprints.xhtmlInformation about commercial reprint orders: 
http://journals.asm.org/site/subscriptions/To subscribe to to another ASM Journal go to: 
 o
n
 February 24, 2014 by Cardiff Univ
http://cvi.asm
.org/
D
ow
nloaded from
 
 o
n
 February 24, 2014 by Cardiff Univ
http://cvi.asm
.org/
D
ow
nloaded from
 
CLINICAL AND VACCINE IMMUNOLOGY, Sept. 2010, p. 1381–1389 Vol. 17, No. 9
1556-6811/10/$12.00 doi:10.1128/CVI.00100-10
Copyright © 2010, American Society for Microbiology. All Rights Reserved.
Microneedle Delivery of H5N1 Influenza Virus-Like Particles to the
Skin Induces Long-Lasting B- and T-Cell Responses in Mice
Jae-Min Song,1 Yeu-Chun Kim,1,2 Aleksandr S. Lipatov,3 Marc Pearton,4 C. Todd Davis,3
Dae-Goon Yoo,1 Kyoung-Mi Park,1 Li-Mei Chen,3 Fu-Shi Quan,1 James C. Birchall,4
Ruben O. Donis,3 Mark R. Prausnitz,2† Richard W. Compans,1*†
and Sang-Moo Kang1*†
Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, Georgia1; School of Chemical and
Biomolecular Engineering, Georgia Institute of Technology, Atlanta, Georgia 302322; Influenza Division, National Center for
Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 303223; and
Welsh School of Pharmacy, Cardiff University, Cardiff CF10 3NB, United Kingdom4
Received 15 March 2010/Returned for modification 19 May 2010/Accepted 6 July 2010
A simple method suitable for self-administration of vaccine would improve mass immunization, particularly
during a pandemic outbreak. Influenza virus-like particles (VLPs) have been suggested as promising vaccine
candidates against potentially pandemic influenza viruses, as they confer long-lasting immunity but are not
infectious. We investigated the immunogenicity and protective efficacy of influenza H5 VLPs containing the
hemagglutinin (HA) of A/Vietnam/1203/04 (H5N1) virus delivered into the skin of mice using metal mi-
croneedle patches and also studied the response of Langerhans cells in a human skin model. Prime-boost
microneedle vaccinations with H5 VLPs elicited higher levels of virus-specific IgG1 and IgG2a antibodies,
virus-specific antibody-secreting cells, and cytokine-producing cells up to 8 months after vaccination compared
to the same antigen delivered intramuscularly. Both prime-boost microneedle and intramuscular vaccinations
with H5 VLPs induced similar hemagglutination inhibition titers and conferred 100% protection against lethal
challenge with the wild-type A/Vietnam/1203/04 virus 16 weeks after vaccination. Microneedle delivery of
influenza VLPs to viable human skin using microneedles induced the movement of CD207 Langerhans cells
toward the basement membrane. Microneedle vaccination in the skin with H5 VLPs represents a promising
approach for a self-administered vaccine against viruses with pandemic potential.
Influenza viruses typically cause seasonal epidemics result-
ing in over 200,000 hospitalizations and approximately 36,000
annual deaths in the United States (45). In addition to seasonal
outbreaks, a new pandemic influenza virus strain may emerge
at any time. For example, the novel 2009 H1N1 virus has
spread rapidly throughout the world, resulting in the first in-
fluenza pandemic in the 21st century (6). Indeed, the recent
experience with the 2009 H1N1 virus demonstrates the need to
develop improved methods of immunization, as conventional
vaccination programs showed a significant delay in controlling
the new pandemic spread despite a half-century of experience
with influenza vaccines.
In 1997, the first human cases of infection by highly patho-
genic H5N1 avian influenza viruses were reported, with 6 fa-
talities out of 18 confirmed cases (7, 41). Since 2003, more than
400 human infections with H5N1 viruses have occurred from
recurring H5N1 outbreaks. Accumulating data indicated
that the fatality rates among H5N1-infected individuals are
about 60% (http://www.who.int/csr/disease/avian_influenza).
Although H5N1 viruses isolated from humans retain charac-
teristic features of avian influenza viruses, direct transmission
of this virus among family members has been observed in
Vietnam, Thailand, and Indonesia (31, 46, 50). If these H5N1
viruses were to acquire the properties for efficient transmission
among humans, like the 2009 H1N1 pandemic virus, and if the
fatality rate remains high, this virus would pose a significant
health threat.
It is highly desirable to develop pandemic influenza vaccines
that can be rapidly produced on a large scale and at low cost,
as well as vaccine delivery methods that can achieve mass
vaccination within weeks rather than months. Virus-like parti-
cles (VLPs) have been suggested as a promising candidate
vaccine against influenza viruses. Such influenza VLPs have
been demonstrated to provide protective immunity in experi-
mental animal models (12, 15, 19, 37, 44), and VLP vaccines
against other diseases are in widespread clinical use (18).
The skin is considered an attractive site for vaccination due to
the abundance of Langerhans and dermal dendritic cells (11, 17,
27, 30). Intradermal (i.d.) immunization, i.e., delivering antigens
to the dermal layer in the skin, has been investigated in many
clinical trials (1, 3, 20). In particular, i.d. delivery of influenza
vaccines was reported to induce greater protective immunity in
the high-risk elderly population (16), possibly by stimulating ef-
fective cellular immune responses (51). While the use of syringes
and needles to deliver a liquid formulation of vaccines is the most
common method for delivering i.d. vaccines, the injection is pain-
ful and difficult to perform in a reproducible manner and requires
highly trained medical personnel.
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Microneedles have been developed to facilitate simple and
effective vaccination without using hypodermic needles (13,
34). Because they can be prepared in a patch format, mi-
croneedles are envisioned to be administered easily and
quickly by minimally trained personnel, or possibly by patients
themselves. Metal microneedles coated with whole inactivated
influenza viruses were demonstrated to deliver the antigen
cargo through the restrictive stratum corneum skin barrier,
eliciting protective immunity (23, 36, 53). In this study, we
tested the feasibility of microneedle vaccination using influ-
enza H5 (A/Vietnam/1203/04) VLPs. Vaccination by mi-
croneedles coated with H5 VLPs in the skin induced protective
immunity in mice equivalent to or higher than that from con-
ventional intramuscular immunization. Importantly, we pro-
vide evidence that these findings could be relevant for human
vaccines because human Langerhans cells (LCs) responded to
influenza VLP vaccines delivered by coated microneedles.
MATERIALS AND METHODS
Cells, virus, and reagents. SF9 insect cells for the production of recombinant
baculoviruses (rBVs) and VLPs were cultured in SF900-II SFM medium at 27°C.
The wild-type influenza A/Vietnam/1203/04 virus (A/VN/1203/04) isolated from
a fatal human infection was used in animal challenge studies, and a reassortant
virus, termed rgH5N1, which contains hemagglutinin (HA) and neuraminidase
derived from H5/VN and internal proteins from A/PR/8/34 (H1N1) virus, was
inactivated and used as an enzyme-linked-immunosorbent assay (ELISA) anti-
gen as described previously (19).
Preparation and characterization of influenza H5 VLPs. Influenza H5 VLPs
containing H5 HA and M1 proteins derived from influenza A/VN/1203/04 virus
were produced using the rBV expression system, as previously described (19).
The protein concentration of H5 VLPs was quantified with a protein assay kit
(Bio-Rad), and the content of HA was determined by Western blotting using the
purified H5 HA protein as a standard. The biological activity of the HA protein
of VLPs was determined by a hemagglutination assay as previously described
(19).
Fabrication and coating of microneedle arrays. Stainless steel microneedle
arrays were fabricated using laser cutting and electropolishing (21). For vaccine
coating, a microneedle array was dipped six times into a coating solution using a
dip-coating device (21) and then air dried at room temperature. The coating
solution consisted of 1% (wt/vol) carboxymethylcellulose sodium salt (Carbo-
Mer), 0.5% Lutrol F-68 NF (BASF) in the absence or presence of 15% (wt/vol)
D-()-trehalose dihydrate (Sigma Aldrich) and 1 mg/ml H5 VLPs in phosphate-
buffered saline (PBS). Images of uncoated and coated microneedle arrays were
taken by bright-field microscopy (Olympus) with a charge-coupled device (CCD)
camera as described previously (21).
Immunization and viral-challenge infection. Female 7- to 8-week-old BALB/c
mice (n  15; Harlan) were vaccinated in the skin using microneedles as de-
scribed previously (21). Briefly, an array with five microneedles coated with a
total of 0.4 g of H5 VLP vaccine protein was manually inserted into the back
skin of the mice and left for 5 to 10 min. For intramuscular (i.m.) immunization
groups, 0.4 g unprocessed H5 VLPs in PBS or redissolved H5 VLPs from
coated microneedles in 50 l PBS (i.m.-R) were injected intramuscularly in the
upper quadriceps muscles of mice. Both microneedle and i.m. immunization sites
were close to the draining inguinal lymph nodes, where antigen presentation
occurs (22). The control mice received microneedles without VLPs (mock).
Treatment with the microneedle patches apparently did not induce irritation or
distress to the animals. To determine the amount of H5 VLP vaccine with which
the microneedles were coated, vaccine-coated microneedles were incubated in
PBS for 12 h at 4°C, and the amount of protein was measured. Mice (n  9 out
of 15) that were immunized using microneedles or intramuscularly at weeks 0
and 8 were transferred to enhanced animal biosafety level (BSL) 3 facilities
(CDC, Atlanta, GA) for challenge studies at 16 weeks after boost. The challenge
dose of 500 PFU A/VN/1203/04 virus (50 times the mouse 50% lethal dose
[LD50]) was used to inoculate mice intranasally. Mice with body weight loss of
25% after inoculation were euthanized. To determine the virus titer, tissues
collected at day 4 postchallenge (n  3 out of 9 challenged mice) were homog-
enized, and the virus titer was quantified by plaque assay on MDCK cells using
methods described previously (19).
Serum antibody responses and HI titers. Influenza virus-specific antibodies of
different isotypes and hemagglutination inhibition (HI) titers were determined
using standard methods, as described previously (19). Briefly, 4 g of inactivated
influenza H5N1 virus was used as a coating antigen on 96-well microtiter plates
(Nunc, Rochester, NY). Serially diluted serum samples were added and incu-
bated for 1 h at 37°C, and then horseradish peroxidase (HRP)-conjugated goat
anti-mouse IgG, IgG1, and IgG2a were used as secondary antibodies with O-
phenylenediamine as a substrate. Standard IgG molecules were used to deter-
mine the antibody concentrations in immune sera from readings at 450 nm. For
determination of HI titers, receptor-destroying enzyme-treated serum samples
(25 l) were incubated with equal volumes of inactivated H5N1 virus (4HAU) at
room temperature (RT) for 30 min. After incubation, an equal volume of 1%
horse erythrocytes was added and incubated at RT for 1 h. The HI titer was
expressed as the reciprocal of the highest dilution of the samples preventing
hemagglutination.
Virus-specific recall immune responses. Mice vaccinated with H5 VLPs i.m.
and through microneedle procedures (n  6 out of 15 mice per group) were
exposed to the inactivated rgH5N1 virus (1 g) via the intranasal route 6 days
prior to sacrifice. Antibody-secreting cell responses in the bone marrow and
spleens were determined after 2 or 6 days of in vitro culture as described
previously (19).
ELISPOT assay for determination of T-cell responses. Splenocytes were iso-
lated from immunized mice and cultured in Multiscreen 96-well filtration plates
coated with capture antibodies against mouse gamma interferon (IFN-) or
interleukin 4 (IL-4) cytokine (1.0  106 cells/well). The spleen cell cultures were
stimulated for 36 h at 37°C with an HA1 or HA2 subunit peptide pool (10 g/ml)
derived from A/Thailand/16/04 (H5N1), which has 99% homology with VN/04
HA. Cytokine IFN-- or IL-4-producing cell spots were developed with stable
3,3-diaminobenzidine and counted using an ImmunoSpot enzyme-linked immu-
nospot (ELISPOT) reader as previously described (19).
Langerhans cell distribution in excised human skin. LC distribution studies
were performed in surgically removed but still viable human skin, obtained under
informed consent and with full ethical approval at Cardiff University. Mi-
croneedle arrays were coated as described previously (21) to deliver H5 VLPs (10
g) to the human skin following a 5-min insertion period. The treated regions of
skin were excised and placed in an optimized air-liquid interface organ culture
system, detailed elsewhere (4, 28, 32). To determine LC numbers in the epider-
mis following VLP microneedle treatment, immunohistochemical staining of
human epidermal sheets was achieved using established protocols (28). Briefly,
human epidermal sheets were incubated in 0.03% (vol/vol) H2O2 for 5 min and
then incubated for 1 h with CD207 mouse monoclonal antibody (Abcam). The
epidermal sheets were visualized by light microscopy to count the LCs.
Histological skin sections (4 m) were generated (Leica 2125 RT microtome;
Milton Keynes, United Kingdom) and captured on Superfrost Plus slides. The
slides were rehydrated through an ethanol gradient and subjected to heat-me-
diated antigen retrieval in Tris-EDTA buffer (10 mM Tris base, 1 mM EDTA,
0.05% [vol/vol] Tween 20 in 1 liter double-diluted H2O [ddH2O] adjusted to pH
9.0) at 95°C for 40 min, following which the slides were maintained in antigen
retrieval buffer but allowed to cool for 20 min at room temperature. The slides
were washed in two changes of PBS-Tween prior to incubation in 0.03% H2O2
for 5 min at room temperature. Detection and visualization of CD207 were the
same as for epidermal sheets. The LC distance from the basement membrane
was determined in immunohistochemical (IHC)-stained sections using ImageJ
software.
Statistical analysis. Every assay was measured using three to six samples, from
which the arithmetic mean and standard error were calculated. A two-tailed
paired Student’s t test was performed when two groups of animals were com-
pared. A P value of 0.05 was considered statistically significant.
RESULTS
Coating microneedles with influenza H5 VLPs. The mi-
croneedles used in this study were approximately 700 m in
length and 50 m in cross section at the base (Fig. 1A) to allow
penetration into the epidermal and dermal layers of skin (13,
21, 23, 53). The microneedles were coated with influenza H5
VLPs containing HA from H5N1 (A/VN/1203/04) virus and air
dried. A bright-field micrograph of the microneedles after they
were coated with influenza H5 VLPs is shown in Fig. 1A. The
amount of influenza H5 VLPs coated onto an array with 5
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microneedles was 0.4 g of VLPs, as determined after elution
in PBS (Fig. 1B). The addition of trehalose to the coating
solution was previously shown to stabilize inactivated influenza
virus vaccines (36). We also found that H5 VLPs were stabi-
lized by the presence of trehalose during microneedle coating,
as indicated by the retention of over 65% of the hemaggluti-
nating activity after elution of VLPs from microneedles into
PBS (Fig. 1C). Trehalose itself did not show any hemaggluti-
nation activity (data not shown). In contrast, microneedle coat-
ing without trehalose resulted in almost complete loss of the
hemagglutinating activity of H5 VLP vaccines (Fig. 1C).
Microneedle vaccination with H5 VLP induces higher IgG
levels. To assess the importance of HA stabilization, mice were
vaccinated using microneedles coated with H5 VLP (0.4 g
total protein) formulation containing trehalose (MN) or lack-
ing trehalose (MN) into the skin of mice. As comparative
controls, groups of mice were intramuscularly immunized with
untreated H5 VLPs (0.4 g; designated i.m.) or H5 VLPs (0.4
g) previously redissolved from coated microneedles (desig-
nated i.m.-R) containing trehalose at weeks 0 and 8 (Fig. 2A).
Thus, the i.m.-R group was immunized with an amount of H5
VLP formulation equivalent to that of the microneedle group
(MN), allowing direct comparison between the routes of de-
livery. Immunization with microneedles coated with H5 VLPs
without trehalose (MN) did not induce significant levels of
antibodies specific for H5N1 virus, and no immune response
was observed in this group after boost (Fig. 2A). Microneedles
coated with H5 VLPs in trehalose as a stabilizer (MN) elic-
ited the highest levels of IgG antibodies specific for H5N1 virus
after prime-boost vaccination (Fig. 2A). Both i.m. groups
(i.m.-R with trehalose and i.m. with untreated H5 VLP vaccine
without trehalose) vaccinated with H5 VLPs intramuscularly
induced similar IgG antibody responses at the 8-week time
point, which were significantly lower than those observed in the
trehalose-stabilized microneedle group (MN) (P  0.01).
The presence of the trehalose stabilizer did not significantly
affect host immune responses, as shown in the i.m.-R group.
Therefore, these results indicate that microneedle vaccination
in the skin was more immunogenic than i.m. immunization. In
addition, trehalose was found to stabilize the H5 VLP vaccines,
which was an important factor for maintaining their immuno-
genic property.
The pattern of antibody isotypes provides insight into the
Th1/Th2 polarization of the immune response induced by mi-
croneedle vaccination with H5 VLPs. As shown in Fig. 2B and
C, microneedle vaccination (MN) induced significantly
higher levels of both IgG1 (Fig. 2B) (P 0.01) and IgG2a (Fig.
2C) (P  0.05) antibody responses than in the i.m. groups.
Moreover, the ratios of IgG1 to IgG2a elicited by microneedle
vaccination were more balanced than those elicited by intra-
muscular vaccination after boost immunization (Fig. 2D). Mi-
croneedle vaccination induced levels of HI titers 40 and 80%
higher than those induced by intramuscular vaccination with
intact H5 VLPs (i.m.) and redissolved vaccines from mi-
croneedles (i.m.-R), respectively, although there was no statis-
tical significance (Fig. 3). These results indicate that there is no
good correlation between binding antibodies and HI titers.
Previous studies demonstrated that cross-protective immunity
against influenza viruses was observed in the absence of de-
tectable HI titers, indicating that nonneutralizing antibodies
also contribute to protection (35, 43, 49). Overall, delivery of
H5 VLP vaccines in a dry state to the skin using coated mi-
croneedles induced higher levels of IgG1 and IgG2a antibody
responses and HI titers similar to intramuscular vaccination
with liquid formulations.
Microneedle vaccination with H5 VLPs provides protection
against lethal H5N1 challenge. To further determine the effi-
cacy of microneedle vaccination with H5 VLPs, groups of vac-
cinated mice, including a mock control, were challenged with
50 times the mouse 50% lethal dose (LD50) of A/VN/1203/04
(H5N1) virus at 16 weeks after vaccination (Fig. 4). All mice in
the mock control group lost body weight rapidly and had to be
euthanized by day 7 or 8 postchallenge. The group of mice that
received microneedle vaccination with trehalose-stabilized H5
VLPs (MN) was completely protected against lethal chal-
lenge infection (Fig. 4B) and showed a slight increase in body
weight. The corresponding intramuscular group (i.m.-R) that
FIG. 1. Coating microneedles with H5 VLPs. (A) A microneedle
array coated with influenza H5 VLPs is shown as a bright and bulky
shape under the micrograph. Influenza H5 VLP-coated microneedles
with or without trehalose were used for microneedle vaccination in the
skin or redissolved for characterization and intramuscular injection of
H5 VLPs in PBS from coated microneedles. (B) H5 VLP vaccine doses
on microneedles. The amounts of total protein are represented for an
array with 5 microneedles coated with vaccine alone or with VLPs in a
trehalose-containing formulation. (C) HA activities (percent of un-
processed control) were determined after dissolving H5 VLP vaccines
from microneedles coated or not with trehalose formulation. The data
are presented as means 	 standard errors.
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received the same H5 VLP trehalose vaccine as in microneedle
applications showed a transient but significant body weight
loss, on average up to 7.8% compared to the microneedle
group (P  0.05), at day 6 postchallenge (Fig. 4A).
Effective control of viral replication in challenge-inoculated
animals is an important indicator for assessing the protective
efficacy of vaccination. Thus, we also determined the virus
titers in lungs, spleens, and brains of inoculated mice on day 4
postinfection. High viral titers in both lungs and spleens were
detected in the mock-vaccinated control group, indicating sys-
temic spread of the challenge virus (Fig. 4C). All mice vacci-
nated with H5 VLPs either intramuscularly (i.m. and i.m.-R) or
via microneedles (MN) showed 2 to 3 log units lower lung
viral titers than mock-vaccinated counterparts, and virus was
never detected in other organs. Although no statistical differ-
ence between the microneedle and intramuscular groups was
apparent, these results do indicate that microneedle vaccina-
tion with H5 VLP vaccines in the skin provides effective pro-
tection in mice.
Microneedle vaccination with H5 VLPs induces long-lived
antibody-producing B cells. The longevity of antibody-produc-
ing B cells had not been previously investigated after mi-
croneedle vaccination. To determine the H5N1 virus-specific
memory B and plasma cell responses, we analyzed spleen (Fig.
5A) and bone marrow (Fig. 5B) cell populations at 8 months
after microneedle vaccination with H5 VLPs. Vaccinated or
mock control mice were restimulated by intranasal exposure to
inactivated rgH5N1 virus 6 days prior to harvesting of spleen
and bone marrow cells for ex vivo culture. The levels of virus-
specific IgG antibodies were low at day 2 of in vitro culture.
Interestingly, after 6 days of in vitro culture, significantly higher
levels of virus-specific antibodies were secreted into the culture
supernatants of splenocytes from mice that received mi-
croneedle vaccination than from those vaccinated intramuscu-
larly (Fig. 5A). Similarly, more than 2.5-fold-higher levels of
virus-specific antibodies were secreted in the bone marrow
cells from the microneedle-vaccinated group after the 6 days of
in vitro culture than from the intramuscularly immunized
group (Fig. 5B). These results indicate that virus-specific anti-
body-producing precursor cells with memory B-cell character-
FIG. 2. Total IgG antibody responses and isotypes specific to H5N1 influenza virus. Groups of mice were immunized using microneedles or
intramuscular injection at weeks 0 and 8. Virus-specific IgG antibody titers (A), IgG1 (B) and IgG2 (C) isotypes, and the ratios of IgG1 to IgG2a
isotypes (D) were determined at 8 weeks after prime or boost vaccination. The data represent mean protein concentrations 	 standard errors of
1:100 diluted serum samples from individual mice (n  9). Mock, microneedle vaccination without vaccine; MN, vaccination using microneedles
coated with 0.4 g H5 VLPs in the absence of trehalose; MN, vaccination using microneedles coated with 0.4 g H5 VLPs in the presence of
trehalose; IM-R, intramuscular immunization with 0.4 g H5 VLPs redissolved from coated microneedles with trehalose formulation; IM,
intramuscular immunization with 0.4 g unprocessed (intact) H5 VLPs. Each group contained 9 BALB/c mice. The asterisks indicate significant
differences (*, P  0.05; **, P  0.01).
FIG. 3. HI titers. Serum samples from individual mice (n 9) were
collected at 8 weeks after boost immunization, and HI titers were
determined by standard methods using 4 HA units of inactivated
rgH5N1 virus and 1% horse erythrocyte suspension. The groups were
as described in the legend to Fig. 2. The data are presented as means	
standard errors.
1384 SONG ET AL. CLIN. VACCINE IMMUNOL.
 o
n
 February 24, 2014 by Cardiff Univ
http://cvi.asm
.org/
D
ow
nloaded from
 
istics were strongly induced in both spleens and bone marrow
after microneedle H5 VLP vaccination and that these cells can
respond rapidly upon viral antigenic exposure.
Microneedle vaccination with H5 VLPs induces cellular im-
mune responses. Cellular immune responses 8 months follow-
ing immunizations were determined by analyzing IL-4- and
IFN--secreting splenocytes upon stimulation by a pool of H5
HA peptides. Splenocytes isolated from vaccinated mice were
stimulated in vitro with a pool of HA1 or HA2 subunit peptide
derived from A/Thailand/16/04 (H5N1) influenza virus (Fig.
6). Splenic cell spots secreting IFN- were observed in re-
sponse to the stimulation with the HA1, but not the HA2,
peptide pool at 2-fold-higher levels in the group of mice that
received microneedle vaccination with H5 VLPs in the skin
than in the intramuscular-immunization group (P 0.01) (Fig.
6A). Similarly, approximately 1.5-fold-higher levels of IL-4-
secreting spleen cell spots were detected after microneedle
vaccination with H5 VLPs than after intramuscular immuniza-
tion (P  0.05) (Fig. 6B). Overall, these results indicate that
microneedle vaccination with H5 VLPs effectively induces both
Th1 and Th2 types of immune responses, as demonstrated by
the patterns of cytokines.
Microneedle vaccination with H5 VLPs induces movement
of Langerhans cells in human epidermis. To complement an-
imal studies, excised human breast skin explants were used to
determine whether microneedle vaccination with H5 VLPs
affected the LC population in human epidermis. The numbers
of LCs in human skin were monitored and counted during
organ cultures at different time points. Figure 7A and B show
that while the number of LCs in human epidermal sheets was
affected by changes in the environment following skin excision
and organ culture over 24 and 48 h (untreated skin), the re-
duction in LC numbers at both of these time points was sig-
nificantly more pronounced in skin that had been treated with
FIG. 4. Protection against lethal challenge with the wild-type H5N1 virus. Groups of vaccinated mice and a mock control (PBS) were
intranasally challenged with 50 LD50 of A/VN/1203/04 virus (n  9 per group). (A and B) Body weight changes (A) and survival rates (B) were
recorded for 14 days. (C) Challenge virus titers in the lungs, spleens, and brains of mice were determined by plaque assay on MDCK cells. The
dotted line in panel C indicates the detection limit of virus titers (50 PFU per ml). The groups were as described in the legend to Fig. 2. The data
are presented as means 	 standard errors.
FIG. 5. Antibody-secreting cell responses. Antibody-secreting cell responses from spleen cells (A) and bone marrow cells (B) were determined
by ELISA 8 months after immunization with microneedles or intramuscular injection. Splenocytes and bone marrow cells were obtained from mice
(n  6) exposed to inactivated rgH5N1 virus 6 days before sacrifice and then cultured in vitro. Culture supernatants harvested on day 2 and day
6 were used to determine the levels of IgG antibodies specific for H5N1 virus. The data are presented as means 	 standard errors. The asterisks
indicate significant differences (**, P  0.01).
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microneedles coated with H5 VLPs. LC numbers in control
samples treated with microneedles alone and microneedles
coated with placebo coating formulation did not significantly
deviate from untreated skin (data not shown). Analysis of skin
sections further confirmed that the distribution of LCs was
altered following treatment with microneedles coated with H5
VLPs. Figure 7C shows a general trend of LC relocalization
from their central epidermal location toward the basement
membrane following exposure to the VLPs. These results pro-
vide support for the notion that interaction of VLP antigens
FIG. 6. Cytokine-secreting cell responses. IFN--secreting (A) and IL-4-secreting (B) cell spots were determined by ELISPOT assay. Groups
of mice (n  6) that were immunized with H5 VLPs by microneedles or intramuscularly 8 months earlier were antigenically challenged with
inactivated rgH5N1 virus 6 days prior to sacrifice. The cytokine-secreting cellular immune responses were measured by ELISPOT assay using
splenocytes isolated from immunized mice. The data are presented as means 	 standard errors. The asterisks indicate significant differences
(*, P  0.05; **, P  0.01).
FIG. 7. Change in Langerhans cell distribution in response to H5 VLP microneedle treatment in human epidermal sheets. (A) LC numbers in
human skin. The numbers of LCs were determined from randomly chosen, digitally captured images at40 magnification corresponding to an area
of 0.04 mm2. H5 VLPs were delivered by coated microneedles. Significance was determined relative to untreated skin (*, P  0.05) at the
corresponding time point. The data are presented as means 	 standard errors (n  4). (B) Representative LC images from each time point (bars,
20 m). Human LCs were visualized by staining the surface marker CD207 with mouse monoclonal antibody as described in Materials and
Methods. (C) LC localization to epidermal basement membrane (BM). Shown are the mean distances (	standard deviations) of LCs from the
basement membrane in untreated and H5 microneedle-treated (H5 VLP MN) skin samples, both following 24 h of incubation in culture. **,
significant difference (P  0.01). The inset shows magnified sections of untreated (i) and H5 VLP MN-treated (ii) skin (bars, 50 m).
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with LCs may result in their stimulation for subsequent move-
ment in human skin.
DISCUSSION
In an attempt to improve H5N1 vaccine delivery approaches,
we have determined the immunogenicity and protective effi-
cacy elicited by microneedle administration of an H5 VLP
antigen to mouse skin. Our results indicate that prime-boost
microneedle vaccination in the skin with low doses of H5 VLPs
can induce long-lasting humoral and cellular immune re-
sponses, as well as protective immunity. Higher levels of anti-
body-secreting cell responses in both spleen and bone marrow
were found to be induced by the microneedle vaccination than
by traditional intramuscular immunization when determined at
8 months postvaccination. More importantly, we found that
microneedle delivery of H5 VLP vaccines to viable human skin
can mobilize CD207 human LCs. In addition, microneedle
vaccination has logistic advantages, such as potential self-ad-
ministration and avoiding the use of hypodermic needles and
syringes. Therefore, the results in this study have significant
implications in demonstrating the feasibility of microneedle
vaccination for humans.
We showed that an H5 VLP vaccine delivered via a surface
coating on microneedles induces protective immunity at least
comparable to that induced by intramuscular immunization.
VLPs alone would not cross the skin barrier at a meaningful
level, as we have shown that the immune responses without
microneedles were minimal even with over 200-fold-higher
doses (100 g) of inactivated whole virus applied to the skin
(39). The VLP doses used for microneedle vaccination were
0.4 g total protein containing approximately 40 ng of HA
(19). The immunogenicity of egg-derived inactivated subunit
H5N1 vaccines administered without adjuvants in preclinical
and clinical studies was far less satisfactory than that of sea-
sonal influenza vaccines (14, 26, 42). We found that a single
dose of microneedle vaccination with H5 VLPs induced low
levels of antibody responses, which is consistent with results
showing low immunogenicity of H5 vaccines in previous stud-
ies. High doses and/or multiple injections of H5 vaccines were
needed to obtain satisfactory seroconversion rates. In humans,
two 90-g HA doses of baculovirus-expressed or inactivated
subunit vaccines produced in eggs were needed to induce an-
tibody responses that were expected to be protective in 54 to
58% of individuals vaccinated (5, 24, 29, 47, 48). A prime-boost
immunization regimen of adjuvanted inactivated H5N1 whole
virus or a split vaccine containing 3 g HA has been applied to
induce protective immunity or to improve protective efficacy in
mice (9, 25, 40). Our results demonstrated that significant
levels of H5-specific antibodies were induced after prime-boost
vaccination with an even lower dose of H5 VLPs via either
microneedle skin delivery or the intramuscular route. There-
fore, our study suggests that VLPs are an effective immunogen
for inducing protective immunity against H5N1 influenza virus
via microneedle vaccination in the skin.
The microneedles used in this study were designed to deliver
coated vaccines in a dry form to the epidermis and dermis of
the skin, as previously described (21, 23, 34, 53). H5 VLPs
delivered to the skin via microneedles induced effective hu-
moral and cellular immune responses after boost immuniza-
tion, including IgG1 and IgG2a isotype antibodies and cyto-
kine (IFN- and IL-4)-secreting splenocytes, which were
observed to be significantly higher in the microneedle group
than in the intramuscular group. Microneedle immunization
also induced more balanced immune responses than the intra-
muscular route, including both T helper type 1 (Th1) and Th2,
as shown by increases in both IgG1 and IgG2a antibody levels
after boost vaccination. In contrast, intramuscular immuniza-
tion with influenza VLPs induced IgG2a antibody as a domi-
nant isotype, probably due to preferential activation and dif-
ferentiation of conventional B2 cells to secrete IgG2a isotype
antibody by VLP immunization (52). It was previously re-
ported that epidermal gene gun delivery of DNA vaccines
induced IgG1 as a dominant antibody, as well as IFN-- and
IL-4-secreting T-cell responses (10, 33), whereas the same
DNA vaccines delivered by intramuscular injection induced a
Th1 pattern of immune responses, including IgG2a (10, 33).
Therefore, the route of vaccination can influence the pattern
of immune responses, as well as protective efficacy.
It was demonstrated that aggregates of inactivated split in-
fluenza vaccines can influence the Th1/Th2 immune responses
by increasing the Th2-type cytokine-producing cells (IL-4 and
IL-5), but not by changes in the ratios of antibody isotypes
IgG1 and IgG2a (2). Microneedle vaccination with inactivated
influenza H1N1 viral vaccines (A/PR/8/34) without trehalose
stabilization induced high IgG1 and low IgG2a antibody levels
compared to trehalose-stabilized microneedle vaccination,
which was partially attributed to the formation of particle ag-
gregates (21). A Th2-type immune response was implicated as
being undesirable in humans (2). Thus, it is important to im-
prove the Th1-type immune responses after microneedle vac-
cination with H5 VLPs. Although trehalose stabilization was
shown to prevent the formation of influenza vaccine aggregates
and to induce higher levels of IgG2a antibodies (21), the low
immunogenicity of H5 vaccines (A/VN/1203/04) might also
have contributed to the types of immune responses. Mi-
croneedle coating with H5 VLPs needs further investigation to
improve Th1-type immune responses.
A recent study demonstrated that simian-human immuno-
deficiency VLPs trafficked to and were associated with local
lymph nodes for longer times after intradermal immunization
on the abdominal site than after intramuscular injection of
mice and resulted in enhanced immune responses (8). Also, we
demonstrated that microneedle delivery on the dorsal skin can
load a model compound into dendritic cells, more effectively
draining to the local lymph nodes than intramuscular injection,
using a fluorescent dye as a model compound (22). These
studies indicate that different anatomical sites of the skin did
not significantly affect immune responses in a mouse model,
but it remains to be determined in humans. Our complemen-
tary experiments investigated the effects on LCs after delivery
of VLPs from coated microneedles using a previously validated
excised-human-skin model (28). Importantly, this study dem-
onstrated that the numbers of human CD207 LCs in a given
epidermal plane were significantly lower after administration
of influenza H5 VLP vaccine to the skin using microneedles.
Tissue sections further confirmed changes in the LC distribu-
tion pattern following VLP exposure, suggesting their mobili-
zation in the human skin environment. VLP vaccines were
shown to effectively activate dendritic cells, enhancing the cell
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surface activation markers CD80 and CD86 (38). Therefore,
effective uptake and stimulation of antigen-presenting cells,
such as LCs, by delivery of particulate VLP vaccines to the skin
is likely to be a mechanism for inducing long-lasting immune
responses, as evidenced by high levels of antibody-secreting
B-cell responses and IFN- cytokine-producing T cells after
skin vaccination.
Vaccine delivery using coated microneedles is a new plat-
form for vaccination. The vaccines are delivered in a dry for-
mulation, and delivery does not involve hypodermic needles
and syringes. The patch-based format of microneedles should
simplify vaccination and may enable self-administration. Pro-
duction of VLP vaccines does not require the handling of live
influenza viruses during vaccine manufacture and does not rely
on problematic egg supplies. Therefore, microneedle vaccina-
tion with VLPs provides an attractive approach to improve
both vaccination efficacy and coverage for seasonal and pan-
demic viruses that warrants further studies.
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